KyungDong Pharm home
Prescription Medicines

Litamezin SR Tab. 2.5/1000mg

Product Category
diabetes medication
Active Ingredients
Linagliptin (micronized), metformin hydrochloride
Appearance
Yellow, oval, sustained-release film-coated tablets
Reimbursement Code
648105000
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Linagliptin (micronized) (in-house specification) · · · · · · · 2.5mg
Metformin hydrochloride (EP) · · · · · · · · 1000mg
- Additives: Microcrystalline cellulose, magnesium stearate, Opadry yellow (03B22082), copovidone, colloidal silicon oxide, croscarmellose sodium, sodium bicarbonate, hypromellose

2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes who are suitable for combined administration of linagliptin and metformin.

3. Dosage and dosage
In anti-diabetic therapy, the dosage of this drug is determined considering the current treatment, effectiveness and tolerability of each patient within a range not exceeding the maximum recommended daily dose of 5 mg of linagliptin and 2000 mg of sustained-release metformin hydrochloride, respectively.
Take this medicine once a day with a meal, preferably with dinner. To reduce the gastrointestinal side effects associated with metformin use, increasing the dose of metformin hydrochloride should be done slowly.
To maintain its sustained-release properties, this medication should be swallowed without breaking, crushing, grinding, or chewing. This medication may be incompletely dissolved and excreted in the feces. It is not known whether the substance excreted in feces contains the active ingredient of the drug. If the patient repeatedly reports that this drug has been found in the stool, the medical staff should evaluate whether blood sugar is adequately controlled (see Precautions for Use, Section 5. General Precautions).
This 5/1000 mg sustained-release tablet is taken once a day, one tablet at a time.
Patients taking this 2.5/1000 mg sustained-release tablet should take 2 tablets at a time, once a day.
1. If you are not currently being treated with metformin:
The initial dose of this drug is 5 mg of linagliptin and 1,000 mg of metformin hydrochloride per day, and the dose of metformin hydrochloride can be gradually increased up to the highest recommended daily dose of 2,000 mg.
2. If you are being treated with metformin
- The initial dose of this drug for patients who cannot adequately control blood sugar levels with metformin monotherapy is a total daily dose of 5 mg of linagliptin and the existing dose of metformin hydrochloride, depending on the patient's current treatment regimen.
- For patients who cannot sufficiently control blood sugar levels with metformin and sulfonylurea combination therapy or metformin and insulin combination therapy, the initial dose of this drug should be considered to be a total daily dose of 5 mg of linagliptin and a dose similar to the existing dose of metformin hydrochloride. When this drug is administered in combination with insulin or sulfonylurea, a reduction in the dose of insulin or sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use 2. Administer with caution to the following patients).
- When switching from an immediate-release form of metformin to a sustained-release form, blood sugar control should be closely monitored, and the dose should be adjusted appropriately if necessary.
- When switching from the combination therapy of linagliptin and sustained-release metformin to this drug, the dosage of this drug is the existing dosage of linagliptin and sustained-release metformin hydrochloride.
special group
renal impairment
Since dose adjustment is necessary depending on renal function, it is recommended to evaluate renal function before and periodically after administration of this drug.
Patients with mild renal impairment [creatinine clearance (CrCl) ? 60 mL/min or estimated glomerular filtration rate (eGFR)? 60mL/min/1.73 m2], no dosage adjustment of this drug is necessary.
In patients with moderate renal impairment (CKD stage 3A) with a creatine clearance (CrCl) greater than 45 mL/min and less than 60 mL/min or an estimated glomerular filtration rate (eGFR) greater than 45 mL/min/1.73 m2 and less than 60 mL/min/1.73 m2, if the drug is well tolerated and there are no other symptoms that may increase the risk of lactic acidosis, the dose of metformin hydrochloride may be adjusted as follows. It can be used through
The starting dose of metformin hydrochloride is 500 mg or 750 mg once a day, so treatment with this drug should not be started. The maximum daily dose of metformin hydrochloride is 1000 mg.
If creatinine clearance (CrCl) decreases below 45 mL/min or estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2, this drug should be discontinued immediately.

4. Precautions for use
1. Warning
metformin hydrochloride
In rare cases, severe lactic acidosis or hypoglycemia may occur. Cases of death due to lactic acidosis have been reported.

2. Do not administer to the following patients
1) Patients with hypersensitivity to linagliptin and/or metformin hydrochloride, the main ingredients of this drug, or to the components of this drug
2) Patients with type 1 diabetes, lactic acidosis, or diabetic ketoacidosis
3) Diabetic precoma patient
4) Patients with more severe (stage3b) renal impairment or renal failure (creatinine clearance (CrCl) <45 ml/min or glomerular filtration rate (eGFR) <45mL/min/1.73m2)
5) Acute conditions that may change renal function, such as dehydration, severe infection, severe traumatic systemic disorder, shock, acute myocardial infarction, sepsis, and intravenous administration of radioiodinated contrast media.
6) Diseases that can cause tissue hypoxemia, such as decompensated heart failure or pulmonary infarction, respiratory failure such as severe pulmonary dysfunction, recent myocardial infarction, and shock (especially acute disease or exacerbation of chronic disease)
7) Patients with liver dysfunction (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), patients with gastrointestinal disorders such as diarrhea and vomiting
8) Acute alcohol poisoning
9) Alcoholism
10) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
11) Patients with acute and unstable heart failure
12) Pregnant women at risk of placental insufficiency, preeclampsia, and intrauterine growth retardation
13) Patients with myocardial infarction and its history

3. Administer with caution in the following patients:
1) Hypoglycemia: Linagliptin alone showed an equivalent incidence of hypoglycemia as placebo. In a clinical trial of linagliptin used in combination with other agents (metformin, thiazolidinedione) that were not considered to cause hypoglycemia, the incidence of hypoglycemia with linagliptin was reported to be similar to that in the placebo group.
Sulfonylureas and insulin are known to cause hypoglycemia, so caution is required when using this drug with sulfonylureas or insulin, and a dose reduction of sulfonylureas or insulin may be considered.
Under normal circumstances, metformin administered alone does not cause hypoglycemia, but hypoglycemia may occur when caloric intake is insufficient, during excessive exercise without replenishing calories, or when used together with other drugs or ethanol that lower blood sugar levels, such as sulfonylurea or insulin.
2) Lactic acidosis: Lactic acidosis is very rare, but it can be caused by the accumulation of metformin hydrochloride and is a serious metabolic complication with a high mortality rate if there is no immediate treatment. Lactic acidosis, which has been reported in patients taking metformin, occurs frequently in the setting of acute renal function deterioration, cardiopulmonary disease, and sepsis. Special caution must be taken in situations where renal function may be impaired (e.g., when there are symptoms of dehydration (severe or persistent vomiting or diarrhea) or when starting medications that affect renal function (such as antihypertensive agents or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). It is necessary. In these acute situations, metformin should be discontinued immediately and temporarily.
To avoid lactic acidosis, other related risk factors such as poor glycemic control, ketosis, long-term fasting, excessive alcohol consumption, liver dysfunction, and other situations related to hypoxia (decompensated heart failure, acute myocardial infarction) should be considered (see 2. Do not administer to the following patients).
The risk of lactic acidosis should be considered when non-specific symptoms such as muscle cramps, digestive disorders such as abdominal pain, and myasthenia gravis occur. Patients, especially those who have previously tolerated metformin well, should be instructed to notify their physician immediately if these symptoms occur. Stop taking metformin, at least temporarily, until the situation becomes clear. Resumption of metformin should be discussed considering renal function and the individual patient's benefit/risk ratio.
Diagnosis: Lactic acidosis is characterized by acid dyspnea, asthenia, abdominal pain, and hypothermia leading to coma. Laboratory diagnostic findings include decreased blood pH (<7.35), blood lactic acid content exceeding 5 mmol/L, anion gap, and increased lactic acid/piburic acid ratio. When this drug is believed to be the cause of lactic acidosis, blood concentrations of this drug are generally found to exceed 5 μg/mL. If lactic acidosis occurs, you must be hospitalized immediately (see 11. Treatment in case of overdose).
Doctors should inform patients of the risks and symptoms of lactic acidosis.
3) Renal function: Since metformin hydrochloride is mainly excreted by the kidneys, blood creatinine concentration should be measured before starting treatment and periodically thereafter.
- Patients with normal renal function: measured at least annually
- Patients and elderly people whose blood creatinine concentration reaches the upper limit of the normal range: Measure at least 2 to 4 times a year
This drug should not be administered if CrCl <45mL/min (eGFR <45mL/min/1.73m2) (see 2. Do not administer to the following patients).
In elderly people, renal function decline is frequent and asymptomatic. For example, special caution is required in situations where renal function may be impaired, such as when starting treatment for dehydration or high blood pressure or diuretics, or when starting treatment with non-steroidal anti-inflammatory drugs.
In these cases, it is also recommended to evaluate renal function before starting metformin treatment.
4) Heart function
Patients with heart failure are at high risk of hypoxia and renal failure. This drug can be used with periodic monitoring of cardiac and renal function in patients with stabilized chronic heart failure.
5) Administration of radioiodinated contrast medium: Intravenous injection of iodinated contrast medium in radiological examinations may lead to contrast medium-induced renal failure, which may increase the risk of metformin accumulation and lactic acidosis. Metformin medication should be discontinued before or at the time of the imaging examination, should not be administered until at least 48 hours after the examination, and may be administered only after renal function has been reassessed and renal function is judged to be stable.
6) Surgery
Metformin hydrochloride should be discontinued 48 hours before elective surgery under general, spinal, or epidural anesthesia. Administration of metformin hydrochloride can be resumed only when normal renal function is assessed to have recovered 48 hours after surgery or after resumption of oral nutrition.
7) Congestive heart failure: Because experience with administration is limited in patients with New York Heart Association (NYHA) functional class I-II congestive heart failure, it should be used with caution in these patients. Because there is no clinical experience in NYHA functional class III-IV patients, the use of this drug is not recommended.
8) Pancreatitis: Acute pancreatitis was observed in patients taking linagliptin. After discontinuation of linagliptin administration, improvement in pancreatitis was observed. Patients taking this medicine should be informed of the characteristic symptoms of acute pancreatitis (persistent and severe abdominal pain), and if pancreatitis is suspected, taking this medicine should be discontinued.
9) Pemphigus vulgaris: Pemphigus vulgaris was observed in patients taking linagliptin. If pemphigoid is suspected, you should stop taking this medicine.

4. Adverse reactions
The safety of linagliptin 2.5 mg twice daily (or 5 mg once daily) in combination with metformin was evaluated in more than 6,800 patients with type 2 diabetes.
In a placebo-controlled clinical trial, linagliptin 2.5 mg twice daily (or 5 mg once daily) was administered in combination with metformin to more than 1800 patients for 12/24 weeks.
As a result of the integrated analysis of this placebo-controlled clinical trial, the overall adverse reaction rate was similar in the placebo and metformin group and the linagliptin 2.5 mg and metformin combination group (54.3%, 49.0%). Discontinuation of treatment due to adverse reactions was similar in the placebo and metformin group and the linagliptin and metformin combination group (3.8%, 2.9%).
Because of the influence of the underlying treatment drug on adverse reactions such as hypoglycemia, adverse reactions were analyzed and displayed based on linagliptin and metformin and each treatment prescription of metformin, sulfonylurea, and linagliptin.
This placebo-controlled clinical trial included 7 trials using linagliptin in addition to metformin and 1 trial using linagliptin in addition to metformin + sulfonylurea.
The following adverse reactions occurred in clinical trials or post-marketing experience with linagliptin/metformin combination administration or single administration (linagliptin or metformin) therapy and are shown in the table below. Previously reported adverse reactions to any of the individual components may be potential adverse reactions to this drug, even if they were not observed in clinical trials of this drug. For all adverse reactions, the frequency of occurrence is listed for each site of occurrence, and the following definitions are used for frequency; Very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥ 1/1,000 to <1/100), rare (≥ 1/10,000 to <1/1,000), very rare (< 1/10,000), unknown (cannot be estimated from available data).
* Table: refer to manual
1 Adverse reactions reported in patients receiving linagliptin alone
2 Adverse reactions reported with metformin alone; For additional information regarding metformin, refer to the product's label.
3 Adverse reactions from combined administration of linagliptin and metformin (integrated analysis results of placebo-controlled trials)
4 Adverse reactions based on post-marketing experience of linagliptin
5 Adverse reactions reported in patients receiving a fixed-dose combination of linagliptin and metformin and in patients receiving metformin alone
* Long-term metformin administration has been associated with decreased vitamin B12 absorption, which may very rarely lead to clinically serious vitamin B12 deficiency such as megaloblastic anemia.
** The most frequent adverse reactions that occurred in the early stages of metformin hydrochloride treatment were gastrointestinal disorders such as abdominal pain, nausea, vomiting, diarrhea, and decreased appetite, which recovered naturally in most cases. To prevent these adverse reactions, when administering metformin hydrochloride alone, it is recommended to take the two-day dose during or after a meal.
§ See Linagliptin Cardiovascular and Renal Safety Study (CARMELINA)
† Increase >3 times the upper limit of normal
ψ According to the CAROLINA study comparing linagliptin with the active comparator glimepiride (see Clinical Trial Information section), laboratory analysis of amylase showed an increase >3 times the upper limit of normal in 0.99% of linagliptin patients and 0.54% of glimepiride patients.
In placebo-controlled clinical trials, the most frequently reported adverse reaction when administering linagliptin and metformin was diarrhea (1.6%), which was a similar incidence to that when administering metformin and placebo (2.4%).
Adverse reactions when linagliptin and metformin are administered together with sulfonylureas:
When linagliptin and metformin were administered together with sulfonylurea, hypoglycemia was the most frequently reported adverse reaction (23.9% in the linagliptin + metformin + sulfonylurea group vs. 16.0% in the placebo group) and was confirmed to be an additional adverse reaction in this situation. None of the hypoglycemia cases were classified as severe.
Adverse reactions when linagliptin and metformin are administered together with insulin:
When linagliptin and metformin were administered together with insulin, hypoglycemia was the most frequently reported adverse reaction, occurring at a similar frequency as when placebo and metformin were administered together with insulin (linagliptin + metformin + insulin group 29.5% vs. placebo + metformin + insulin group 30.9%), and serious events occurred at a lower frequency (1.5% vs. 0.9%).
Linagliptin Cardiovascular and Renal Safety Study (CARMELINA)
The CARMELINA study investigated the cardiovascular and renal safety of linagliptin compared to placebo in patients with type 2 diabetes at high cardiovascular risk based on underlying macrovascular or renal disease (see Section 12. Information for Experts). The study included 3494 patients receiving linagliptin (5 mg) and 3485 patients receiving placebo. Administration of linagliptin did not increase the risk of major cardiovascular disease, hospitalization for heart failure, or renal outcomes. The incidence of total and serious adverse events in patients receiving linagliptin was similar to that in patients receiving placebo.
In the treatment group, severe cases of hypoglycemia were reported in 3.0% of those receiving this drug and 3.1% of those receiving placebo. The incidence of severe hypoglycemia in patients treated with sulfonylurea at baseline was 2.0% in the drug-treated group and 1.7% in the placebo-treated group. In patients taking insulin at baseline, the incidence of severe hypoglycemia was 4.4% in the drug-treated group and 4.9% in the placebo-treated group.
During the entire study observation period, a diagnosis of acute pancreatitis was reported in 0.3% of patients receiving this drug and 0.1% of patients receiving placebo.
Pseudo-wrapping was reported in 0.2% of patients receiving this drug, and was not reported in the placebo group.
※ Domestic post-marketing survey results (linagliptin (single drug))
As a result of a post-marketing survey conducted on 3,119 people over 6 years to reexamine linagliptin (single drug) in Korea, the occurrence rate of adverse events was reported to be 7.69% (240/3,119 people, 313 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
* Table: refer to manual
※ Domestic post-marketing survey results (linagliptin/metformin hydrochloride (immediate-release type) (combined drug))
As a result of a post-marketing survey conducted on 709 people over a period of 5 years for re-examination in Korea, the occurrence rate of adverse events was reported to be 11.99% (85/709 people, 98 cases in total) regardless of causal relationship. Among these, serious adverse events unrelated to a causal relationship and serious adverse drug reactions for which a causal relationship cannot be ruled out are listed in the table below according to the frequency of occurrence.
* Table: refer to manual
In addition, unexpected adverse events unrelated to causal relationships and unexpected adverse drug reactions for which causal relationships cannot be ruled out are listed in the following table according to the frequency of occurrence.
* Table: refer to manual

5. General precautions
1) Severe and disabling joint pain
Severe and disabling arthralgia have been reported in post-marketing studies in patients taking DPP-4 inhibitors. The onset of symptoms after drug administration varied from 1 day to several years later. Symptoms were alleviated when drug administration was stopped. In some patients, recurrence of symptoms occurred when taking the same drug or a different DPP-4 inhibitor. Consider the DPP-4 inhibitor as the cause of severe arthralgia and, if appropriate, discontinue administration.
2) Bullous pemphigoid
Bullous pemphigus requiring hospitalization has been reported in patients taking DPP-4 inhibitors. Patients generally recovered with discontinuation of DPP-4 inhibitors and treatment with topical or systemic immunosuppressants. Patients should be advised to immediately report to their doctor if blisters or sores occur while taking this medication. If bullous pemphigoid is suspected, discontinue this drug and consult a dermatologist for diagnosis and appropriate treatment.
3) Vitamin B12
Metformin can decrease vitamin B12 levels.
The risk of low vitamin B12 levels increases in patients with higher metformin doses, longer treatment duration, and/or with risk factors known to cause vitamin B12 deficiency. If vitamin B12 deficiency is suspected (such as anemia or neuropathy), serum vitamin B12 levels should be monitored. Patients with risk factors for vitamin B12 deficiency may require regular vitamin B12 monitoring. Metformin therapy should be continued unless metformin is tolerated and contraindicated, and appropriate corrective treatment for vitamin B12 deficiency should be provided according to current clinical guidelines.
4) This medicine should be swallowed whole rather than crushed or chewed. Patients should be informed in advance that this is normal as the tablet shell may pass through the stool.

6. Interaction
(1) General
Co-administration of linagliptin 10 mg once daily and metformin 850 mg twice daily in healthy volunteers did not cause significant pharmacokinetic changes to linagliptin or metformin.
Although studies on pharmacokinetic drug interactions have not been conducted for this drug, studies have been conducted on linagliptin and metformin, respectively.
(2) Linagliptin
Laboratory evaluation of drug interactions
Linagliptin is a weak, mechanistic, weak to moderate inhibitor of the CYP isozyme CYP3A4, but does not inhibit other CYP isozymes and is not an inducer of CYP isozymes. Linagliptin is a P-glycoprotein substrate and weakly inhibits digoxin transport by P-glycoprotein. Based on these results, and in drug interaction studies in animals, it is believed that linagliptin does not cause interactions with other P-glycoprotein substrates.
In vivo evaluation of drug interactions
The clinical data described below indicate that the risk of clinically significant interactions with coadministered drugs is low. No clinically significant interactions requiring dose adjustments were observed.
Linagliptin has not shown clinically relevant effects with metformin, glibenclamide, simvastatin, pioglitazone, warfarin, digoxin, or oral contraceptives and has demonstrated a low tendency to cause drug interactions with CYP3A4, CYP2C9, CYP2C8, P-glycoprotein, and organic cation transporter (OCT) substrates.
Metformin: Co-administration of metformin 850 mg three times daily and supratherapeutic doses of linagliptin 10 mg once daily in healthy volunteers did not result in clinically significant changes in the pharmacokinetics of linagliptin or metformin. Therefore, linagliptin is not an organic cation (OCT)-mediated transporter inhibitor.
Sulfonylurea: The steady-state pharmacokinetics of linagliptin 5 mg were not changed by single administration of glibenclamide (glyburide) 1.75 mg or multiple oral administration of linagliptin 5 mg. However, both AUC and Cmax of glibenclamide were reduced by 14%, which was not clinically relevant. Because glibenclamide is primarily metabolized by CYP2C9, these data also support the conclusion that linagliptin is not a CYP2C9 inhibitor. Clinically significant interactions are not expected with other sulfonylureas that are primarily eliminated by CYP2C9, such as glibenclamide.
Thiazolidinedione: Co-administration of 10 mg/day of linagliptin, a CYP2C8 and CYP3A4 substrate, with 45 mg/day of pioglitazone did not show clinically relevant effects on the pharmacokinetics of linagliptin, pioglitazone, or the active metabolite of pioglitazone, indicating that linagliptin is not an inhibitor of CYP2C8-mediated metabolism in vivo. This supports the conclusion that in vivo inhibition of CYP3A4 by
Ritonavir: A study was conducted to evaluate the effect of ritonavir, a potent P-glycoprotein and CYP3A4 inhibitor, on the pharmacokinetics of linagliptin. As a result of the combined use of a single dose of 5 mg linagliptin and 200 mg oral multiple doses of ritonavir, the AUC and Cmax of linagliptin increased by 2-fold and 3-fold, respectively. Simulations of steady-state plasma concentrations of linagliptin alone or in combination with ritonavir confirmed that increased exposure was not associated with increased accumulation. These changes in linagliptin pharmacokinetics are not believed to be clinically relevant. Therefore, clinically relevant interactions with other P-glycoprotein/CYP3A4 inhibitors are not expected and no dose adjustments are required.
Rifampicin: A study was conducted to evaluate the effect of rifampicin, a potent inducer of P-glycoprotein and CYP3A4, on the pharmacokinetics of linagliptin 5 mg. Repeated co-administration of linagliptin and rifampicin decreased the AUC and Cmax of linagliptin in the steady state by 39.6% and 43.8%, respectively, and decreased DPP-4 inhibition in the trough state by 30%. Therefore, the combined use of a strong P-gp inducer and linagliptin is judged to be clinically effective, even if the complete medicinal effect cannot be achieved.
Digoxin: Coadministration of linagliptin 5 mg and digoxin 0.25 mg in healthy volunteers did not affect the pharmacokinetics of digoxin. Therefore, linagliptin is not an inhibitor of P-glycoprotein mediated transport in vivo.
Warfarin: Linagliptin administered at 5 mg daily did not change the pharmacokinetics of S(-) or R(+) warfarin, which are CYP2C9 substrates, indicating that linagliptin is not a CYP2C9 inhibitor.
Simvastatin: In healthy volunteers, linagliptin administered at a dose of 10 mg/day had a minimal effect on the steady-state pharmacokinetics of simvastatin, a sensitive CYP3A4 substrate. When 10 mg of linagliptin and 40 mg of simvastatin were administered for 6 days, the blood AUC of simvastatin increased by 34% and blood Cmax increased by 10%. Therefore, linagliptin is considered to be a weak inhibitor of CYP3A4-mediated metabolism, and dose adjustment of co-administered drugs metabolized by CYP3A4 is not necessary.
Oral contraceptives: Coadministration of linagliptin 5 mg did not alter the steady-state pharmacokinetics of levonorgestrel or ethinyl estradiol.
The absolute bioavailability of linagliptin is approximately 30%. Because there was no clinically relevant effect on its pharmacokinetics when administered with a high-fat diet, linagliptin can be administered with or without a meal.
(3) Metformin
1) Metformin, one of the active ingredients of this drug, increases the risk of lactic acidosis in cases of acute alcohol intoxication (especially in cases of fasting, malnutrition, or liver failure). You should avoid taking alcohol and alcohol-containing drugs.
2) Drugs that may affect this drug, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Since OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
3) Intravenous administration of iodinated contrast media in radiological examinations can cause renal failure, ultimately leading to metformin accumulation and the risk of lactic acidosis.
In patients with eGFR >60 mL/min/1.73m2, this medication should be discontinued before or at the time of testing, should not be administered until at least 48 hours after testing, and may be administered only after renal function has been reassessed and determined to be no longer declining.
In patients with moderate renal impairment (eGFR 45-60 mL/min/1.73m2), this drug should be discontinued 48 hours prior to the test, should not be administered until at least 48 hours after the test, and may be administered only after renal function has been reassessed and determined to be no longer reduced.
4) Since the blood sugar-lowering effect may be enhanced or decreased by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that enhance blood sugar lowering action
Insulin preparations, sulfonamide and sulfonylurea drugs, α-glucosidase inhibitors, anabolic steroids, guanethidine, salicylates (aspirin, etc.), β-blockers (propranolol, etc.), MAO inhibitors
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazides and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
5) Furosemide: A study on the drug interaction between this drug and furosemide as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of this drug without significant changes in its renal clearance, increasing blood Cmax by 22% and blood AUC by 15%. When administered together with this drug, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when this drug is co-administered with furosemide chronically.
6) Nifedipine: A study on the drug interaction between this drug and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of this drug in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine enhances the absorption of this drug. This drug does not significantly affect nifedipine.

7. Administration to pregnant and lactating women
1) Pregnancy: There are no adequate, well-controlled studies conducted on pregnant women with this drug or any of its active ingredients. In a non-clinical reproductive toxicity test conducted with this drug in pregnant rats, no teratogenicity was found due to combined administration of linagliptin and metformin.
As a precaution, this medication should be avoided during pregnancy.
For patients who are pregnant or planning pregnancy, insulin should be used to maintain blood glucose as close to normal as possible and reduce the risk of fetal malformations associated with abnormal glucose levels.
2) Breastfeeding
No studies have been conducted on combined administration of metformin and linagliptin in lactating animals. In animal experiments, linagliptin and its metabolites were observed to be excreted through breast milk. Metformin is secreted in human milk, and it is not known whether linagliptin is secreted in human milk. Therefore, this drug should not be used during breastfeeding.
3) Raw food
Although no studies have been conducted to investigate the effect of this drug on human reproductive function, no toxic effects of linagliptin on reproductive function were observed in non-clinical studies conducted up to the highest dose of 240 mg/kg/day, which is more than 900 times the dose in humans.

8. Administration to children
Safety and efficacy in children have not been established.

9. Administration to elderly people
Metformin is mainly excreted through the kidneys, and since aging is associated with decreased renal function in elderly patients, the minimum dose that achieves appropriate blood sugar control effects should be set based on the patient's renal function. Elderly patients should have their renal function monitored regularly, and maximum doses are generally not administered to elderly patients.

10. Effects on driving and machine operation
No studies have been conducted on the effects on driving and operating machinery.

11. Treatment in case of overdose
1) Symptoms
In clinical trials conducted in healthy subjects, single doses of linagliptin up to 600 mg (equivalent to 120 times the recommended dose) were well tolerated. There is no experience of using more than 600 mg in humans.
When up to 85 g of metformin hydrochloride was used, lactic acidosis occurred, but hypoglycemia was not observed. Overuse of metformin hydrochloride or the accompanying risks may cause lactic acidosis. Lactic acidosis is a medical emergency and should be treated in a hospital.
2) Treatment
In case of overdose, it is recommended to perform general supportive treatment, such as removing unabsorbed drug from the gastrointestinal tract, clinically monitoring, and administering necessary clinical measures. The most effective way to remove lactate and metformin is hemodialysis.

12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful as changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
3) Store away from moisture.

13. Information for experts
1) Pharmacological action
This drug is a sustained-release combination drug containing linagliptin and metformin hydrochloride for the purpose of improving blood sugar control in patients with type 2 diabetes. Linagliptin selectively inhibits dipeptidyl peptidase-4 (dpp-4), thereby enhancing glucose-mediated insulin secretion (incretin effect). Metformin is known to lower blood sugar and insulin resistance in the liver or fat cells through a mechanism that inhibits gluconeogenesis in the liver.
2) Pharmacokinetic information
This drug (5/1000 mg) and previously approved medicines (linagliptin 5 mg single agent and metformin hydrochloride (extended release) 1000 mg single agent) were administered single orally to healthy adults in a 2 In this case, the 90% confidence interval of the geometric mean ratio was within 80.00~125.00%, proving biological equivalence. In a separate test, metformin in the blood of 34 people was measured by administering one tablet each after a meal to healthy adults in a 2×2 cross-over test of the test drug and the reference drug. When the comparative evaluation item values ​​(AUCt, Cmax) were log-transformed and processed statistically, the 90% confidence interval of the geometric mean ratio was within 80.00-125.00%, demonstrating biological equivalence.
Note 1. This drug was manufactured using the same raw materials as Genuine Science Co., Ltd.'s Tracaiduo Extended-Release Tablet 2.5/1000 mg (linagliptin, metformin hydrochloride) and the entire process was outsourced to Genuine Science Co., Ltd. using the same manufacturing method.
3) Clinical trial information
Additional use of linagliptin to metformin monotherapy
The efficacy and safety of the addition of linagliptin in patients who did not achieve adequate glycemic control with metformin monotherapy were evaluated in a double-blind, placebo-controlled trial lasting 24 weeks. At week 24, linagliptin showed improvement in glycated hemoglobin (HbA1c) compared to placebo (0.64% change compared to placebo). In addition, linagliptin showed a decrease in fasting plasma glucose (FPG) (-21.1 mg/dL) and a decrease in 2-hour post-prandial glucose (2h-PPG) (-67.1 mg/dL) compared to placebo, and the proportion of patients achieving HbA1c less than 7% was higher compared to placebo.
In a 104-week clinical trial comparing the efficacy and safety of the additional use of linagliptin with glimepiride in patients who did not have adequate glycemic control with metformin monotherapy, the HbA1c reduction effect of this drug was non-inferior to glimepiride by +0.20% (95% CI 0.09, 0.299) (non-inferiority margin 0.35%).
The efficacy and safety of linagliptin 2.5 mg twice daily compared with linagliptin 5 mg once daily in patients with inadequate glycemic control on metformin monotherapy were evaluated in a double-blind, placebo-controlled trial lasting 12 weeks. The additional combination of linagliptin 2.5 mg twice daily or linagliptin 5 mg once daily showed a statistically significant decrease in HbA1c compared to placebo (-0.74% and -0.80% change compared to placebo, respectively), and the HbA1c improvement effect of linagliptin 2.5 mg twice daily when additionally administered to metformin was linagliptin 5 mg. It was similar to the mg once daily dosage.
Initial combination use of metformin and linagliptin
The efficacy and safety of the initial combination of linagliptin and metformin were evaluated in a 24-week placebo-controlled, double-blind, factorial study in patients who had not previously received diabetes medication or who did not achieve sufficient glycemic control with monotherapy. Linagliptin 2.5 mg and metformin 500 mg or linagliptin 2.5 mg and 1000 mg twice daily showed significant improvement in blood glucose-related parameters compared to the two drugs alone (Table 1). In general, it was greater in patients with higher HbA1c compared to baseline.
Table 1. Results of a 24-week clinical trial comparing the initial combination of linagliptin and metformin with each monotherapy in type 2 diabetes patients with insufficient blood sugar control through diet and exercise.
* Table: refer to manual
* The total daily dose of linagliptin is the same at 5 mg.
**p-value<0.0001
Additional use of linagliptin for metformin and sulfonylurea combination therapy
The efficacy and safety of the addition of linagliptin in patients who did not achieve adequate glycemic control with metformin and sulfonylurea combination therapy were evaluated in a placebo-controlled trial lasting 24 weeks. At week 24, linagliptin showed a significant improvement in HbA1c compared to placebo (-0.62% change compared to placebo). In addition, the proportion of patients who achieved HbA1c less than 7.0% with linagliptin was higher compared to placebo, and the FPG reduction compared to placebo was -12.7 mg/dL.
Addition of linagliptin to metformin and empagliflozin combination therapy
In a 24-week, double-blind, placebo-controlled trial, linagliptin was added for patients with inadequate glycemic control on metformin plus empagliflozin (10 mg or 25 mg). The baseline-adjusted mean reductions in HbA1c versus placebo were statistically significant: 0.32% with background metformin plus empagliflozin 10 mg and 0.47% with background metformin plus empagliflozin 25 mg. Among patients with baseline HbA1c of at least 7%, the proportion achieving the target HbA1c below 7% was significantly higher than with placebo.
In a predefined subgroup analysis of patients with baseline HbA1c ≥8.5% (n = 66 and n = 42, respectively, on background metformin and empagliflozin 10 mg or metformin and empagliflozin 25 mg), the reduction in baseline-adjusted mean HbA1c at week 24 for the add-on combination of linagliptin compared to placebo, respectively. were ?0.33% (p=0.0875) and ?0.62% (p=0.0046).
Addition of linagliptin to metformin and insulin combination therapy
The efficacy and safety of the addition of linagliptin in patients who did not achieve adequate glycemic control with metformin and insulin combination therapy were evaluated in a double-blind, placebo-controlled trial lasting 24 weeks. The addition of linagliptin to various insulin regimens (insulin alone, insulin and metformin, insulin and pioglitazone, insulin and metformin and pioglitazone) for 24 weeks resulted in a significant improvement in HbA1c compared to placebo (-0.65% change in HbA1c compared to placebo). In a subgroup analysis according to oral hypoglycemic agent background therapy, the HbA1c reduction effect for insulin and metformin background therapy (76% overall) was similar to the overall result.
Linagliptin Cardiovascular and Renal Safety Study (CARMELINA)
CARMELINA was a randomized study of 6,979 patients with type 2 diabetes at high cardiovascular risk based on an established history of macrovascular or renal disease. Linagliptin 5 mg (3,494 patients) or placebo (3,485 patients) was added to standard care for HbA1c, cardiovascular risk factors, and renal disease. The study included 1,211 patients aged 75 years or older (17.4%) and 4,348 patients with renal disease (62.3%). Approximately 19% had an eGFR of 45 to <60 mL/min/1.73 m², 28% had an eGFR of 30 to <45 mL/min/1.73 m², and 15% had an eGFR below 30 mL/min/1.73 m². Mean baseline HbA1c was 8.0%.
The study was designed to demonstrate non-inferiority for the primary cardiovascular endpoint consisting of a composite of first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (3P-MACE). The renal composite endpoint is defined as kidney disease death or persistent end-stage renal disease (ESRD) or a sustained decrease in eGFR of 40% or more.
After a median follow-up of 2.2 years, linagliptin added to standard treatment did not increase the risk of major adverse cardiovascular events or renal outcome events. When compared to standard treatment type 2 diabetes patients who did not receive linagliptin, there was no increased risk of hospitalization due to heart failure, an additional endpoint.
Table 2. Composite variables and incidence rates according to treatment group in the CARMELINA study
* Table: refer to manual
* PY = patient years
** Non-inferiority trial to demonstrate that the upper limit of the 95% CI for the non-inferiority risk ratio is lower than 1.3.
*** Since more than one case may occur in one subject, the sum of the subjects of each case is greater than the number of all subjects who experienced the case.
Linagliptin cardiovascular safety study (CAROLINA)
CAROLINA was a randomized study in which 6,033 patients with early type 2 diabetes at high cardiovascular risk or with confirmed comorbidities were administered linagliptin 5 mg (3,023 patients) or glimepiride 1-4 mg (3,010 patients) to standard treatment for HbA1c and cardiovascular risk factors (including metformin-based therapy in 83% of patients). The average age of the study subjects was 64 years old, and 2,030 patients (34%) were older than 70 years old. The study population included 2,089 (35%) patients with cardiovascular disease and 1,130 (19%) patients with renal impairment with eGFR less than 60 ml/min/1.73m2 at baseline. The average HbA1c at baseline was 7.15%.
The study was designed to demonstrate non-inferiority for the primary cardiovascular endpoint consisting of a composite of first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (3P-MACE).
After a median follow-up of 6.25 years, linagliptin did not increase the risk of major adverse cardiovascular events (Table 3) compared to glimepiride. The results were consistent regardless of whether the patient was treated with metformin.
Table 3. Major cardiovascular events (MACE) and incidence rates by treatment group in the CAROLINA study
* Table: refer to manual
* PY = patient years
** Non-inferiority trial to demonstrate that the upper limit of the 95% CI for the risk ratio is lower than 1.3
During the total treatment period (median treatment period 5.9 years), the proportion of patients with moderate or severe hypoglycemia was 6.5% in the glimepiride group compared to 30.9% in the glimepiride group, and severe hypoglycemia occurred in 0.3% of the glimepiride group compared to 2.2% in the glimepiride group.
4) Toxicity test information
metformin
(1) Metformin is a primary or secondary regenerating drug or does not exhibit addiction-induced pharmacokinetic properties.
(2) Long-term carcinogenicity tests were conducted on rats (dose lasting 104 weeks) and mice (dose lasting 91 weeks) at doses of 900 mg/kg/day and 1500 mg/kg/day, respectively. This dose is approximately three times the human body's maximum daily allowance based on body surface area. There was no evidence of metformin-related carcinogenicity in either male or female mice. Similarly, there was no tumorigenic potential due to metformin in male rats. However, an increase in benign interstitial uterine polyps was observed in female rats administered at 900 mg/kg/day.
There was no evidence for the mutagenic potential of metformin in reverse mutation assays (S. typhimurim), genetic mutation assays (mouse lymphoma cells), chromosomal aberration assays (human lymphocytes), or in vivo micronucleus assays (mouse bone marrow cells).
Fertility in male and female rats was not affected by metformin when administered at a high dose of 600 mg/kg/day, or approximately twice the maximum tolerated dose based on body surface area.

5. How to save
Store in an airtight container at room temperature (1~30℃), avoiding moisture.

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 1items

No.Product NameDetailsDate of ChangeDownload
1Litamezin SR Tab. 2.5/1000mgPrecautions for use2026.10.02PDF0201_202400185_Precautions for use (Ritamezine extended-release tablet 2.5_1000mg).pdf